GLP-1 RAs for CVD: Are Cardiologists Ready?
The SELECT trial catapulted GLP-1 RAs into the forefront of CVD prevention, but cardiologists are making their own decisions about whether and how they might integrate these agents into practice.
Source: medscape.com